中华整形外科杂志
中華整形外科雜誌
중화정형외과잡지
CHINESE JOURNAL OF PLASTIC SURGERY
2013年
6期
418-421
,共4页
高伟成%王虎军%乔星%马娟%杜金%马少林
高偉成%王虎軍%喬星%馬娟%杜金%馬少林
고위성%왕호군%교성%마연%두금%마소림
异常黑胆质成熟剂%成纤维细胞%细胞凋亡
異常黑膽質成熟劑%成纖維細胞%細胞凋亡
이상흑담질성숙제%성섬유세포%세포조망
Abnormal Savda Munziq%Fibroblast%Apoptosis
目的 探讨维族医药异常黑胆质成熟剂(abnormal savda munziq,ASMq)对体外培养的人增生性瘢痕成纤维细胞增殖及凋亡的作用,为采用维医维药防治增生性瘢痕提供理论依据.方法 体外应用组织块法分离培养增生性瘢痕来源成纤维细胞,采用免疫荧光方法进行鉴定;将成纤维细胞分为6组:①空白对照组:加入等体积的培养液;②ASMq处理组:分成4组,分别加入浓度为0.1、0.4、0.7、1.0 mg/ml的ASMq;③5-Fu组:加入浓度为0.25 mg/ml的5-Fu,为阳性对照组.对各组细胞采用相应药物进行干预,应用CCK8法和流式细胞仪检测各组细胞增殖、细胞周期以及细胞凋亡情况.结果 与空白对照组相比,ASMq对增生性瘢痕来源成纤维细胞增殖有抑制作用,且在0.1 ~ 1.0 mg/ml浓度范围内,随着浓度增加抑制作用呈明显增加;细胞周期测定结果表明抑制于G2/M期,当浓度从0.1 mg/ml增加至1.0 mg/ml后,G2/M期细胞比例从13.1%增加到29.5%(P<0.05);细胞凋亡结果表明ASMq能够诱导Fbs发生凋亡,空白对照组凋亡率为(2.2±0.59)%,而ASMq浓度1.0 mg/ml组凋亡率增加至(43.7±2.58)%,且有明显的浓度依赖性.结论 ASMq具有抑制成纤维细胞增殖,促进凋亡作用,有望成为防治增生性瘢痕的有效药物.
目的 探討維族醫藥異常黑膽質成熟劑(abnormal savda munziq,ASMq)對體外培養的人增生性瘢痕成纖維細胞增殖及凋亡的作用,為採用維醫維藥防治增生性瘢痕提供理論依據.方法 體外應用組織塊法分離培養增生性瘢痕來源成纖維細胞,採用免疫熒光方法進行鑒定;將成纖維細胞分為6組:①空白對照組:加入等體積的培養液;②ASMq處理組:分成4組,分彆加入濃度為0.1、0.4、0.7、1.0 mg/ml的ASMq;③5-Fu組:加入濃度為0.25 mg/ml的5-Fu,為暘性對照組.對各組細胞採用相應藥物進行榦預,應用CCK8法和流式細胞儀檢測各組細胞增殖、細胞週期以及細胞凋亡情況.結果 與空白對照組相比,ASMq對增生性瘢痕來源成纖維細胞增殖有抑製作用,且在0.1 ~ 1.0 mg/ml濃度範圍內,隨著濃度增加抑製作用呈明顯增加;細胞週期測定結果錶明抑製于G2/M期,噹濃度從0.1 mg/ml增加至1.0 mg/ml後,G2/M期細胞比例從13.1%增加到29.5%(P<0.05);細胞凋亡結果錶明ASMq能夠誘導Fbs髮生凋亡,空白對照組凋亡率為(2.2±0.59)%,而ASMq濃度1.0 mg/ml組凋亡率增加至(43.7±2.58)%,且有明顯的濃度依賴性.結論 ASMq具有抑製成纖維細胞增殖,促進凋亡作用,有望成為防治增生性瘢痕的有效藥物.
목적 탐토유족의약이상흑담질성숙제(abnormal savda munziq,ASMq)대체외배양적인증생성반흔성섬유세포증식급조망적작용,위채용유의유약방치증생성반흔제공이론의거.방법 체외응용조직괴법분리배양증생성반흔래원성섬유세포,채용면역형광방법진행감정;장성섬유세포분위6조:①공백대조조:가입등체적적배양액;②ASMq처리조:분성4조,분별가입농도위0.1、0.4、0.7、1.0 mg/ml적ASMq;③5-Fu조:가입농도위0.25 mg/ml적5-Fu,위양성대조조.대각조세포채용상응약물진행간예,응용CCK8법화류식세포의검측각조세포증식、세포주기이급세포조망정황.결과 여공백대조조상비,ASMq대증생성반흔래원성섬유세포증식유억제작용,차재0.1 ~ 1.0 mg/ml농도범위내,수착농도증가억제작용정명현증가;세포주기측정결과표명억제우G2/M기,당농도종0.1 mg/ml증가지1.0 mg/ml후,G2/M기세포비례종13.1%증가도29.5%(P<0.05);세포조망결과표명ASMq능구유도Fbs발생조망,공백대조조조망솔위(2.2±0.59)%,이ASMq농도1.0 mg/ml조조망솔증가지(43.7±2.58)%,차유명현적농도의뢰성.결론 ASMq구유억제성섬유세포증식,촉진조망작용,유망성위방치증생성반흔적유효약물.
Objective To evaluate in vitro effect of abnormal savda munziq (ASMq) on the proliferation and apoptosis of human hypertrophic scar fibroblasts (HSFs).Methods HSFs were divided into six groups to receive different treatments as group A (blank control group),group B-E (ASMq in different concentration),and group F(5-Fu).Each group contains six specimens.The HSFs were cultured in vitro.After culture for 48 hours,The CCK8 test and flow cytometry methods were used to detect the proliferation,cell cycle and apoptosis.Results The proliferation of HSFs in the B,C,D and E groups was inhibited at G2/M period,while it was inhibited at G0/S period in group F(P < 0.05).The inhibition effect of ASMq(0.1 ~ 1.0 mg/ml) on the fibroblasts enhanced in a concentration-dependent manner.Flow cytometry analysis with annexin V-FITC and PI staining confirmed the apoptotic.When HSFs were exposed to ASMq at 1.0 mg/ml (group E) for 48 h,the percentage of apoptotic cells increased to (43.7 ± 2.58) %,which was significantly higher than that of blank control group (2.2 ± 0.59) %.The induced apoptosis effect was also increased in a concentration-dependent manner.Conclusion ASMq has a inhibitory effect on the proliferation and an enhancement effect on the apoptosis of fibroblast.ASMq could be used as an effective drug for treatment of hypertrophic scar.